Exelixis, Inc. (NASDAQ:EXEL) Receives $20.93 Consensus PT from Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus rating of “Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $20.93.

A number of analysts have recently commented on the company. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a research report on Tuesday, July 4th. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Monday, June 26th. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Oppenheimer Holdings, Inc. assumed coverage on Exelixis in a report on Monday, June 12th. They set a “hold” rating on the stock. Finally, TheStreet raised Exelixis from a “d” rating to a “c+” rating in a report on Tuesday, May 2nd.

Shares of Exelixis (NASDAQ:EXEL) traded up 0.83% on Friday, reaching $25.42. The company had a trading volume of 2,164,633 shares. Exelixis has a 12 month low of $7.95 and a 12 month high of $25.71. The firm has a market capitalization of $7.44 billion, a PE ratio of 1210.48 and a beta of 1.88. The firm’s 50 day moving average is $20.79 and its 200 day moving average is $20.23.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Monday, May 1st. The biotechnology company reported $0.05 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.06. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. The business had revenue of $80.90 million for the quarter, compared to analysts’ expectations of $65.23 million. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. The business’s revenue was up 425.3% compared to the same quarter last year. On average, equities research analysts expect that Exelixis will post $0.18 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.wkrb13.com/markets/2285791/exelixis-inc-nasdaqexel-receives-20-93-consensus-pt-from-analysts.html.

In related news, insider Michael Morrissey sold 259,149 shares of the firm’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $22.24, for a total transaction of $5,763,473.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Patrick J. Haley sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 709,647 shares of company stock worth $15,673,068. Corporate insiders own 5.10% of the company’s stock.

A number of large investors have recently made changes to their positions in EXEL. BlackRock Inc. raised its stake in shares of Exelixis by 33,678.5% in the first quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after buying an additional 19,098,757 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Exelixis by 237.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 5,041,260 shares of the biotechnology company’s stock worth $109,244,000 after buying an additional 3,547,665 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Exelixis by 12.8% in the first quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock worth $514,339,000 after buying an additional 2,696,877 shares in the last quarter. Norges Bank acquired a new stake in shares of Exelixis during the fourth quarter worth $36,882,000. Finally, Franklin Resources Inc. acquired a new stake in shares of Exelixis during the fourth quarter worth $16,057,000. 80.69% of the stock is currently owned by institutional investors.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285791/exelixis-inc-nasdaqexel-receives-20-93-consensus-pt-from-analysts.html

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.